Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aquaporin water channels: New perspectives on the potential role in inflammation.

Advances in protein chemistry and structural biology·2019
Same author

Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies.

Cancers·2019
Same author

Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma.

European journal of clinical investigation·2019
Same author

Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment.

Urologic oncology·2019
Same author

Immunophenotypic characterization of telocyte-like cells in pterygium.

Molecular vision·2019
Same author

α-Methyl-prednisolone normalizes the PKC mediated brain angiogenesis in dystrophic mdx mice.

Brain research bulletin·2019
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.6K

Phase II angiogenesis stimulators.

Domenico Ribatti1, Silvia Baiguera

  • 1University of Bari Medical School, National Cancer Institute, Giovanni Paolo II, Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Piazza G. Cesare, 11, Policlinico, 70124 Bari, Italy. domenico.ribatti@uniba.it

Expert Opinion on Investigational Drugs
|June 25, 2013
PubMed
Summary
This summary is machine-generated.

Therapeutic angiogenesis shows promise for ischemic disorders but lacks clinical benefit evidence. Further trials are needed to optimize angiogenic factor delivery and treatment efficacy.

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.5K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.6K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.5K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

9.2K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine

Background:

  • Therapeutic angiogenesis aims to improve oxygen exchange in ischemic conditions like heart attack and stroke.
  • It involves stimulating the growth of new blood vessels and capillaries.

Purpose of the Study:

  • To evaluate the clinical benefit and efficacy of therapeutic angiogenesis.
  • To identify optimal strategies for delivering angiogenic factors.

Main Methods:

  • Review of early clinical trials and large randomized placebo-controlled, double-blinded Phase II trials.
  • Analysis of feasibility, safety, and potential effectiveness data.

Main Results:

  • Early trials showed promise, and Phase II trials confirmed feasibility and safety.
  • However, limited evidence of clinical benefit and efficacy was found.

Conclusions:

  • Current therapeutic angiogenesis trials have yielded unsatisfactory results.
  • Optimal delivery methods, growth factors, and dose regimens require further investigation.
  • More research is essential to enhance treatment benefits for patients with ischemic cardiovascular disorders.